Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Avalo Therapeutics Logo
Avalo Therapeutics Growth Score
71
CB Rank
27156
Heat Score
77
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Founded
obfuscation
PublicPost-IPO Equity Rockville, Maryland, United States11-50 www.avalotx.com
Biotechnology
Therapeutics
Overview

Avalo Therapeutics
Total Funding
obfuscation
Growth Score
71
Heat Score
77

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score71
-8 pts
in past quarter
Heat Score 77
14 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Avalo Therapeutics

CB Rank
27156
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Founded
obfuscation
PublicPost-IPO Equity Rockville, Maryland, United States11-50 www.avalotx.com
Biotechnology
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Avalo Therapeutics, Inc.
Operating Status Active
Stock Symbol  NASDAQ:AVTX
Company Type For Profit
Founders  Isaac Blech
About the Company
Avalo Therapeutics is a clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
Phone Number +1 610-254-4205
Contact Email Info@avalotx.com
Predictions & Insights

Growth Insight

See this Growth Insight
Avalo Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Financial Decline

Products & Services

AVTX-009
AVTX-009 is an anti-IL-1β monoclonal antibody designed to target and treat immune mediated inflammatory diseases.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Deep Track Capital Logo
Deep Track Capital
—
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
Deep Track Capital Logo
Deep Track Capital
—
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
Deep Track Capital Logo
Deep Track Capital
—
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
Deep Track Capital Logo
Deep Track Capital
—
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—
Deep Track Capital Logo
Deep Track Capital
—
Post-IPO Equity - Avalo Therapeutics Logo
Post-IPO Equity - Avalo Therapeutics
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 10 Board Members and Advisors 4 Contacts 30

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,747
523.93%
 in past month

IT Spend

$34KThis year, Avalo Therapeutics is projected to spend $34K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Microsoft (MSFT) Logo
Microsoft (MSFT)
82
Context-Driven Testing Logo
Context-Driven Testing
79
Android Logo
Android
79

Actively Used Products

14Avalo Therapeutics uses 14 technology products and services including HTML5, Google Analytics, and  Apache Server, according to G2 Stack.

Active Website Tech Count

8Avalo Therapeutics is actively using 8 technologies for its website, according to BuiltWith. These include HSTS, Euro, and  CommonCrawl Top 5m.
Sub-Organizations
Frequently Asked Questions

Where is Avalo Therapeutics's headquarters? Avalo Therapeutics is located in Rockville, Maryland, United States.Who invested in Avalo Therapeutics? Avalo Therapeutics has 7 investors including Deep Track Capital and  Biotechnology Value Fund.When was the last funding round for Avalo Therapeutics? Avalo Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Avalo Therapeutics's competitors? Alternatives and possible competitors to Avalo Therapeutics may include Q32 Bio, Alumis, and  Septerna.How much funding has Avalo Therapeutics raised to date? Avalo Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|